AAP
ORKA

Arax Advisory Partners’s Oruka Therapeutics ORKA Stock Holding History

Arax Advisory Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
+1,211
New +$80.7K ﹤0.01% 2623
2025
Q4 		– Sell
-72
Closed -$1.39K – 4604
2025
Q3 		$1.39K Buy
+72
New +$1.07K ﹤0.01% 3187

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arax Advisory Partners's ORKA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 1,211 shares worth $115K. The stake represents ﹤0.01% of the portfolio and ranks #2623 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ORKA as recently as Q3 2025.

Arax Advisory Partners first reported a position in ORKA in Q3 2025 and has held it in 2 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Arax Advisory Partners held 1,211 shares of Oruka Therapeutics worth $115K as of Q2 2026.
  • Oruka Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Oruka Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2623 holding.
  • Arax Advisory Partners first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.